Dapiglutide for the Treatment of Obesity

Summary

This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI \>30 kg/m2) during a 12-week treatment period.

Timeline

Start

2023-04-27

Primary completion

2024-04-24

Completion

2025-08-15

Publications

• Nielsen CK, Palsson TG, Forman JL, Lukacova M, Jensen BAH, Mathiesen DS, Englund A, Gether IM, Johansen NJ, Pedersen MG, Hartmann B, Holst JJ, Knop FK, Lund AB. Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial. EClinicalMedicine. 2026 Feb 21;93:103801. doi: 10.1016/j.eclinm.2026.103801. eCollection 2026 Mar.

Drugs

Indications